» Articles » PMID: 28750095

Serum Tumor-associated Autoantibodies As Diagnostic Biomarkers for Lung Cancer: A Systematic Review and Meta-analysis

Overview
Journal PLoS One
Date 2017 Jul 28
PMID 28750095
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We performed a comprehensive review and meta-analysis to evaluate the diagnostic values of serum single and multiplex tumor-associated autoantibodies (TAAbs) in patients with lung cancer (LC).

Methods: We searched the MEDLINE and EMBASE databases for relevant studies investigating serum TAAbs for the diagnosis of LC. The primary outcomes included sensitivity, specificity and accuracy of the test.

Results: The systematic review and meta-analysis included 31 articles with single autoantibody and 39 with multiplex autoantibodies. Enzyme-linked immunosorbent assay (ELISA) was the most common detection method. For the diagnosis of patients with all stages and early-stage LC, different single or combinations of TAAbs demonstrated different diagnostic values. Although individual TAAbs showed low diagnostic sensitivity, the combination of multiplex autoantibodies offered relatively high sensitivity. For the meta-analysis of a same panel of autoantibodies in patients at all stages of LC, the pooled results of the panel of 6 TAAbs (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2) were: sensitivity 38% (95% CI 0.35-0.40), specificity 89% (95% CI 0.86-0.91), diagnostic accuracy 65.9% (range 62.5-81.8%), AUC 0.52 (0.48-0.57), while the summary estimates of 7 TAAbs (p53, CAGE, NY-ESO-1, GBU4-5, SOX2, MAGE A4 and Hu-D) were: sensitivity 47% (95% CI 0.34-0.60), specificity 90% (95% CI 0.89-0.92), diagnostic accuracy 78.4% (range 67.5-88.8%), AUC 0.90 (0.87-0.93). For the meta-analysis of the same panel of autoantibodies in patients at early-stage of LC, the sensitivities of both panels of 7 TAAbs and 6 TAAbs were 40% and 29.7%, while their specificities were 91% and 87%, respectively.

Conclusions: Serum single or combinations of multiplex autoantibodies can be used as a tool for the diagnosis of LC patients at all stages or early-stage, but the combination of multiplex autoantibodies shows a higher detection capacity; the diagnostic value of the panel of 7 TAAbs is higher than the panel of 6 TAAbs, which may be used as potential biomarkers for the early detection of LC.

Citing Articles

A Predictive Model Integrating AI Recognition Technology and Biomarkers for Lung Nodule Assessment.

Zhou T, Zhu P, Xia K, Zhao B Thorac Cardiovasc Surg. 2024; 73(2):174-181.

PMID: 39591993 PMC: 11884917. DOI: 10.1055/a-2446-9832.


Clinical Value of Seven Autoantibodies Against Tumor-Associated Antigens and Tumor Markers in Lung Cancer Patients: A Retrospective Analysis from a Single Institution.

Ren F, Chen F, Xu X, Ni H, Li T, Ren D Technol Cancer Res Treat. 2024; 23:15330338241293490.

PMID: 39470035 PMC: 11528790. DOI: 10.1177/15330338241293490.


Enhanced Lung Cancer Detection Using a Combined Ratio of Antigen-Autoantibody Immune Complexes against CYFRA 21-1 and p53.

Kim H, Lee J, Kim H, Hong Y Cancers (Basel). 2024; 16(15).

PMID: 39123389 PMC: 11312164. DOI: 10.3390/cancers16152661.


The Immune Response of Cancer Cells in Breast and Gynecologic Neoplasms.

Rakoczy K, Kaczor J, Soltyk A, Szymanska N, Stecko J, Drag-Zalesinska M Int J Mol Sci. 2024; 25(11).

PMID: 38892394 PMC: 11172873. DOI: 10.3390/ijms25116206.


An analysis of the influencing factors of false negative autoantibodies in patients with non-small cell lung cancer.

Wang A, Hao Y, Huo Y, Xu X, Zhang Y Front Oncol. 2024; 14:1358387.

PMID: 38800369 PMC: 11116597. DOI: 10.3389/fonc.2024.1358387.


References
1.
Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C . Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics. 2011; 10(12):M111.010298. PMC: 3237079. DOI: 10.1074/mcp.M111.010298. View

2.
Pedchenko T, Mernaugh R, Parekh D, Li M, Massion P . Early detection of NSCLC with scFv selected against IgM autoantibody. PLoS One. 2013; 8(4):e60934. PMC: 3621672. DOI: 10.1371/journal.pone.0060934. View

3.
Farlow E, Patel K, Basu S, Lee B, Kim A, Coon J . Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010; 16(13):3452-62. DOI: 10.1158/1078-0432.CCR-09-3192. View

4.
Morozova T, Salina T, Zavaleva I . [Enzyme immunoassay and immunochromatographic assay in the differential diagnosis of tuberculosis and cancer of the respiratory organs]. Probl Tuberk Bolezn Legk. 2003; (4):20-2. View

5.
Boyle P, Chapman C, Holdenrieder S, Murray A, Robertson C, Wood W . Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2010; 22(2):383-9. PMC: 3030465. DOI: 10.1093/annonc/mdq361. View